Akums Drugs and Pharmaceuticals
NSE: AKUMS · ISIN INE09XN01023 · Healthcare
₹770.00+26.20 (+3.52%)
Monday 9 November, 13:16 IST. Delayed. Source: Yahoo Finance.
Price chart
₹770.00 +26.20 (+3.52%) today
The day
- Previous close
- ₹743.80
- Open
- ₹740.10
- Day high
- ₹784.90
- Day low
- ₹740.10
Listed on NSE since 6 August 2024.
Key numbers
- Market value
- ₹11,388 Cr
- P/E (trailing)
- 31.30
- EPS (trailing)
- ₹23.76
- Price to book
- 3.25
- Dividend yield
- 0.13%
- Return on equity
- 10.9%
- Debt to equity
- 0.03
- Profit margin
- 7.5%
- Beta
- 0.62
- Volume today
- 5.21 L
- Average volume
- 3.51 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹3,474.76 Cr | ₹94.86 Cr |
| FY24 | ₹4,019.68 Cr | ₹-4.04 Cr |
| FY25 | ₹4,071.09 Cr | ₹338.18 Cr |
| FY26 | ₹4,251.31 Cr | ₹255.19 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹1,342 Cr | ₹113 Cr | +176.7% |
| Q1 FY27Apr–Jun 2026 | ₹1,167 Cr | ₹100 Cr | +57.6% |
| Q4 FY26Jan–Mar 2026 | ₹1,158 Cr | ₹85 Cr | −42.7% |
| Q3 FY26Oct–Dec 2025 | ₹1,160 Cr | ₹66 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹1,018 Cr | ₹41 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹1,024 Cr | ₹63 Cr | – |
Source: Akums Drugs and Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of Akums Drugs and Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹1,769 Cr | ₹1,625 Cr |
| Investments | ₹71 Cr | ₹14.30 L |
| Inventories | ₹903 Cr | ₹756 Cr |
| Owed by customers | ₹859 Cr | ₹797 Cr |
| Cash and equivalents | ₹184 Cr | ₹386 Cr |
| Total assets | ₹5,832 Cr | ₹5,447 Cr |
| Borrowings | ₹36 Cr | ₹73 Cr |
| Total liabilities | ₹2,308 Cr | ₹2,116 Cr |
| Shareholders’ equity | ₹3,503 Cr | ₹3,313 Cr |
Source: Akums Drugs and Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Akums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Delhi
- Employees
- 7,337
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Akums Drugs and Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Dividend - Re 1 Per Share/Special Dividend - Rs 2 Per Share
Dividend · ex-date 3 July 2026
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.